XOMA Royalty completes $4.29 per share acquisition of Generation Bio

XOMA Royalty Corporation (NASDAQ: XOMA) completed its acquisition of Generation Bio Co. (NASDAQ: GBIO) through a tender offer that closed February 6, 2026, the company announced.

Generation Bio stockholders received $4.2913 per share in cash plus one non-tradeable contingent value right. The tender offer attracted 4,722,533 shares, representing approximately 70% of Generation Bio's outstanding common stock as of the expiration date.

Following the tender offer's completion, XRA 7 Corp., a XOMA Royalty subsidiary, merged with Generation Bio. All remaining Generation Bio shares not tendered were converted into the right to receive the same offer price. Generation Bio became a wholly owned subsidiary of XOMA Royalty as a result of the transaction.

Generation Bio shares ceased trading on The Nasdaq Stock Market following the close of trading on February 6. The companies plan to delist the shares from Nasdaq and deregister them under the Securities Exchange Act of 1934.

The tender offer satisfied the minimum tender condition and all other required conditions were satisfied or waived by the expiration deadline of one minute after 11:59 p.m. Eastern Time on February 6, 2026.

TD Cowen served as financial advisor to Generation Bio, while Wilmer Cutler Pickering Hale and Dorr LLP provided legal counsel. Gibson, Dunn & Crutcher LLP represented XOMA Royalty in the transaction.

XOMA Royalty operates as a biotechnology royalty aggregator that acquires future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies.

You May Also Be Interested In